Elepsia Xr 1500 Mg

For adults (16 years and older) with partial-onset, myoclonic, or primary generalized tonic-clonic seizures, the standard starting dose of immediate-release levetiracetam is 500 mg taken twice daily (1000 mg total per day). Depending on how the patient responds and tolerates the medication, a healthcare provider may increase the dose by 1000 mg per day every two weeks. The maximum recommended daily dose is typically 3000 mg per day, divided into two doses. For extended-release formulations, the starting dose is usually 1000 mg once daily, with adjustments made in 1000 mg increments every two weeks up to a maximum of 3000 mg once daily.

Levetiracetam is approved for use in children, but the dosage is strictly based on weight (mg/kg) and age.

• Infants (1 month to <6 months): The starting dose is usually 7 mg/kg twice daily, which may be increased to 21 mg/kg twice daily.
• Infants (6 months to <4 years): The starting dose is usually 10 mg/kg twice daily, increasing up to 30 mg/kg twice daily.
• Children (4 years to <16 years): For children weighing less than 20 kg, weight-based dosing is used. For those over 20 kg, the starting dose is 250 mg twice daily, with a maximum of 750 mg twice daily.

Parents must use a calibrated measuring device for the oral solution to ensure the child receives the exact prescribed amount. Household spoons are not accurate and should never be used.

Renal Impairment

Because levetiracetam is primarily cleared by the kidneys, dosage adjustments are mandatory for patients with impaired renal function. Healthcare providers use the Creatinine Clearance (CrCl) rate to determine the appropriate dose. For patients with severe renal impairment (CrCl <30 mL/min), the dose may be reduced by 50% or more. Patients on hemodialysis require a supplemental dose after each dialysis session because the procedure removes the drug from the bloodstream.

Hepatic Impairment

No dosage adjustment is generally needed for patients with mild to moderate liver disease. However, in patients with severe hepatic impairment, the healthcare provider may check renal function and adjust the dose accordingly, as liver failure can sometimes affect kidney performance.

Elderly Patients

Dosage selection for elderly patients should be cautious, usually starting at the low end of the dosing range. This is primarily because older adults are more likely to have decreased renal function and may be more sensitive to the sedative side effects of the medication.

Levetiracetam should be taken exactly as prescribed by your doctor. It can be taken with or without food, but it is best to take it at the same times each day to maintain a steady level of the drug in your system.

• Immediate-Release Tablets: These should be swallowed with liquid. They can be broken in half if necessary, but check with your pharmacist first.
• Extended-Release (XR) Tablets: These must be swallowed whole. Do not crush, chew, or break them, as this will release the entire dose at once and increase the risk of side effects.
• Oral Solution: Use the provided dosing syringe or a medicinal cup. Mix with a small amount of water if the taste is unpleasant, but ensure the entire mixture is consumed immediately.
• Storage: Store at room temperature (20°C to 25°C or 68°F to 77°F) away from moisture and heat.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed one. Frequent missed doses can trigger "breakthrough seizures," which can be dangerous.

Symptoms of a levetiracetam overdose may include extreme drowsiness, agitation, aggression, decreased consciousness, or difficulty breathing. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. There is no specific antidote for levetiracetam; treatment in a hospital setting involves supportive care and potentially hemodialysis to remove the drug from the system.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can cause status epilepticus.

Most patients tolerate levetiracetam well, but side effects are common, especially during the first few weeks of treatment as the body adjusts. The most frequently reported side effects include:

• Somnolence (Drowsiness): This is the most common side effect. Patients may feel excessively tired or sleepy during the day. This often improves over time.
• Asthenia (Weakness/Fatigue): A general feeling of lack of energy or physical weakness.
• Dizziness: A sensation of spinning or lightheadedness, which can increase the risk of falls.
• Nasopharyngitis: Symptoms similar to the common cold, such as a sore throat or stuffy nose.

• Anorexia: Loss of appetite, which may lead to weight loss in some patients.
• Gastrointestinal Issues: Nausea, vomiting, or diarrhea.
• Coordination Problems: Difficulty with balance or walking (ataxia).
• Diplopia: Double vision or blurred vision.
• Irritability and Mood Changes: Some patients report feeling more easily annoyed or anxious.

• Hematologic Changes: Decreased white blood cell count (leukopenia), decreased neutrophil count (neutropenia), or decreased platelet count (thrombocytopenia). This may increase the risk of infections or bruising.
• Pancreatitis: Inflammation of the pancreas, characterized by severe abdominal pain.
• Hepatic Failure: Rare cases of liver damage have been reported.
• Alopecia: Hair loss, which usually resolves once the medication is stopped.

While rare, some side effects are life-threatening and require immediate intervention:

• Suicidal Thoughts or Behavior: Like all antiepileptic drugs, levetiracetam may increase the risk of suicidal ideation. Monitor for worsening depression, anxiety, or any unusual changes in mood or behavior.
• Severe Dermatological Reactions: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare but fatal skin reactions. Seek help if you develop a painful rash, blisters, or peeling skin, especially accompanied by fever.
• Psychosis and Hallucinations: Some patients may experience a break from reality, seeing or hearing things that aren't there, or experiencing extreme paranoia.
• Anaphylaxis: A severe allergic reaction involving swelling of the face, tongue, or throat, and difficulty breathing.
• Aggression and Hostility: Often colloquially called "Keppra-rage," some patients (particularly children) may experience extreme outbursts of anger or physical aggression.

> Warning: Stop taking Levetiracetam and call your doctor immediately if you experience any of these serious symptoms.

Long-term use of levetiracetam is generally considered safe, but patients should be monitored for persistent behavioral changes. Unlike some other AEDs, levetiracetam is not strongly associated with significant bone density loss (osteoporosis), but regular health check-ups are still advised. There is limited evidence regarding its long-term impact on cognitive function, though most studies suggest it is less cognitively impairing than older drugs like phenobarbital.

Currently, there are no specific FDA Black Box Warnings for levetiracetam. However, the FDA requires a general warning for all antiepileptic drugs regarding the increased risk of suicidal thoughts and behavior. This risk was identified in a pooled analysis of 199 placebo-controlled clinical trials, where the risk of suicidal behavior was approximately twice that of the placebo group (0.43% vs 0.24%).

Report any unusual symptoms to your healthcare provider. Keeping a side-effect diary can help your doctor determine if the medication is the cause of your symptoms and whether a dose adjustment is necessary.

Levetiracetam is a powerful neurological medication that must be used with caution. Patients should never share this medication with others, even if they have similar symptoms. It is vital to maintain regular appointments with your neurologist to monitor the drug's efficacy and safety. Because the drug affects the central nervous system, patients should be aware of how it impacts their mental state and physical coordination.

No FDA black box warnings for Levetiracetam. However, as noted in the side effects section, it carries a standard class-wide warning for all anticonvulsants regarding the risk of suicidal ideation and behavior. Patients, caregivers, and families should be alert for the emergence or worsening of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm.

Allergic Reactions / Anaphylaxis Risk

There is a risk of serious allergic reactions. If you experience hives, swelling of the lips or face, or difficulty breathing, seek emergency care. There have also been reports of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), a multi-organ hypersensitivity reaction that can be fatal.

Behavioral and Psychiatric Abnormalities

Levetiracetam can cause significant psychiatric symptoms. In clinical trials, approximately 13% of adult patients and 38% of pediatric patients experienced behavioral adverse events. These include aggression, agitation, anger, anxiety, apathy, depression, hostility, and irritability. In some cases, these symptoms were severe enough to require discontinuation of the drug.

Withdrawal Seizures

Antiepileptic drugs, including levetiracetam, should be withdrawn gradually to minimize the potential of increased seizure frequency and status epilepticus. If the drug must be discontinued due to a serious adverse event, the transition to another AED should be managed closely by a specialist.

Hematologic Abnormalities

While rare, levetiracetam can cause significant decreases in red blood cell counts, white blood cell counts, and platelets. Patients who develop unexplained fever, sore throat, or easy bruising should have a complete blood count (CBC) performed.

While routine blood level monitoring of levetiracetam is not usually necessary (unlike phenytoin or carbamazepine), it may be useful in certain situations, such as during pregnancy, in patients with kidney failure, or when checking for medication adherence. Periodic monitoring of renal function (kidney tests) is recommended, especially in elderly patients. Behavioral monitoring is the most critical aspect of follow-up care for this specific drug.

Levetiracetam may cause somnolence (sleepiness) and dizziness. Patients should not drive, operate heavy machinery, or engage in potentially hazardous activities until they are reasonably certain that the medication does not affect their ability to perform these tasks safely. Many jurisdictions have specific laws regarding driving for individuals with a history of seizures; consult your doctor and local regulations.

Alcohol can increase the sedative effects of levetiracetam, leading to extreme drowsiness and impaired coordination. Furthermore, alcohol consumption itself can lower the seizure threshold, making the medication less effective at preventing seizures. It is generally advised to avoid or strictly limit alcohol while taking this medication.

Never stop taking levetiracetam abruptly. Sudden cessation can trigger "rebound seizures" or status epilepticus, a life-threatening condition where seizures do not stop. If you need to stop the medication, your doctor will provide a tapering schedule, usually reducing the dose gradually over several weeks.

> Important: Discuss all your medical conditions, including any history of depression or kidney disease, with your healthcare provider before starting Levetiracetam.

There are no absolute drug-drug contraindications where levetiracetam must never be used with another agent, which is one of its primary advantages. However, it should not be used in patients who have had a previous severe allergic reaction to levetiracetam or any of its excipients.

• Methotrexate: Some studies suggest that co-administration of levetiracetam and methotrexate may lead to increased methotrexate blood levels, potentially reaching toxic levels. This is thought to occur through competition for renal excretion pathways. Patients receiving both should have their methotrexate levels monitored closely.
• Probenecid: Probenecid, a medication used for gout, has been shown to inhibit the renal clearance of the primary metabolite of levetiracetam. While the clinical significance is often low, it may increase the risk of side effects in patients with borderline renal function.

• Other CNS Depressants: Medications that cause drowsiness, such as benzodiazepines (e.g., diazepam, lorazepam), opioids, or certain antihistamines, can have an additive effect when taken with levetiracetam. This can lead to severe respiratory depression or extreme sedation.
• Buprenorphine: Similar to other CNS depressants, buprenorphine can increase the sedative effects of levetiracetam. Monitoring for altered mental status is advised.
• Orlistat: This weight-loss medication may potentially decrease the absorption of antiepileptic drugs, including levetiracetam, leading to a loss of seizure control.

Levetiracetam does not have significant interactions with specific foods. Unlike some other medications, it does not interact with grapefruit juice. It can be taken with or without food. However, maintaining a consistent routine (always taking it with food or always without) can help keep blood levels stable.

• St. John's Wort: While levetiracetam is not metabolized by the CYP3A4 enzyme (which St. John's Wort induces), this herb can lower the seizure threshold and should generally be avoided by people with epilepsy.
• Ginkgo Biloba: Ginkgo may contain toxins that can trigger seizures and may interfere with the effectiveness of anticonvulsant medications.
• Valerian and Kava: These herbs have sedative properties and may increase the drowsiness caused by levetiracetam.
• Evening Primrose Oil: This supplement may lower the seizure threshold and should be used with caution.

Levetiracetam is not known to interfere with most common laboratory tests. However, it does not show up on standard urine drug screens for drugs of abuse. If a specific blood level is needed, a specialized assay must be requested from the laboratory.

Mechanism of Interactions

Most interactions involving levetiracetam are pharmacodynamic, meaning the drugs have additive effects on the body (such as increased sedation), rather than pharmacokinetic (where one drug changes the blood level of another). Because levetiracetam avoids the CYP450 liver enzyme system and has low protein binding, it is often the preferred choice for patients on complex medication regimens for HIV, cancer, or organ transplants.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even "natural" products can interfere with seizure control.

An absolute contraindication is a condition where the medication must not be used under any circumstances because the risk clearly outweighs any possible benefit.

• Hypersensitivity to Levetiracetam: Patients who have experienced anaphylaxis, Stevens-Johnson Syndrome, or other severe allergic reactions to levetiracetam or any component of the formulation (such as the tablet coating or oral solution preservatives) must not take the drug. Re-exposure can be fatal.

Relative contraindications are conditions where caution is required, and the drug should only be used if the benefits outweigh the risks.

• Severe Renal Impairment (End-Stage Renal Disease): While not an absolute contraindication, the drug must be used with extreme caution and significant dose reductions. If the kidneys cannot clear the drug, it will accumulate to toxic levels.
• History of Severe Depression or Psychosis: Because levetiracetam is known to cause psychiatric side effects, patients with a pre-existing history of suicidal ideation, severe depression, or violent behavior may be at higher risk for worsening of these conditions. Healthcare providers may prefer an alternative AED for these individuals.
• Pregnancy: While not contraindicated, the risks to the fetus must be weighed against the risk of untreated seizures in the mother. This requires a detailed discussion between the patient and a neurologist.

There is no known cross-sensitivity between levetiracetam and other common antiepileptic classes like sulfonamides (zonisamide), hydantoins (phenytoin), or carboxamides (carbamazepine). However, patients who are sensitive to pyrrolidine derivatives should be monitored closely. Always inform your doctor of any previous drug allergies to ensure a safe prescribing choice.

> Important: Your healthcare provider will evaluate your complete medical history, including your mental health history and kidney function, before prescribing Levetiracetam.

Levetiracetam is frequently used during pregnancy because it is generally considered to have a lower risk of causing major birth defects compared to older drugs like valproate. However, it is not without risk.

• Teratogenicity: Data from pregnancy registries suggest a slightly higher rate of minor malformations compared to the general population, but it is one of the preferred AEDs for pregnant women.
• Physiological Changes: During pregnancy, the body clears levetiracetam much faster. Blood levels can drop significantly, especially in the third trimester, increasing the risk of seizures. Doctors often monitor blood levels monthly and increase the dose as the pregnancy progresses.
• Registry Enrollment: Pregnant women taking levetiracetam are encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry to help collect more safety data.

Levetiracetam passes into breast milk. While many infants do not experience adverse effects, there is a risk of drowsiness, irritability, or poor weight gain in the nursing infant. The decision to breastfeed should be made by weighing the benefits of breastfeeding against the potential risks of drug exposure. If breastfeeding, the infant should be monitored closely for excessive sleepiness.

Levetiracetam is approved for infants as young as 1 month old for partial-onset seizures. It is generally well-tolerated in children, but the risk of behavioral side effects (irritability, aggression) is significantly higher in the pediatric population than in adults. Parents must be vigilant in monitoring their child's mood and behavior. It does not appear to affect growth or bone development significantly.

In patients over 65, the primary concern is age-related decline in kidney function. Since levetiracetam is cleared by the kidneys, the dose must be carefully adjusted based on the patient's creatinine clearance. Elderly patients are also more susceptible to dizziness and somnolence, which can increase the risk of falls and fractures.

For patients with a Creatinine Clearance (CrCl) of 50-80 mL/min, the dose is typically 500-1500 mg every 12 hours. For CrCl 30-50 mL/min, the dose is 250-750 mg every 12 hours. For CrCl <30 mL/min, the dose is 250-500 mg every 12 hours. Patients on dialysis should receive a supplemental dose of 250-500 mg after each session.

No adjustment is needed for mild to moderate hepatic impairment. In severe hepatic impairment (Child-Pugh C), renal clearance may be reduced, so a lower starting dose and careful monitoring are advised.

> Important: Special populations require individualized medical assessment and frequent monitoring by a specialist.

Levetiracetam's primary mechanism involves binding to the Synaptic Vesicle Protein 2A (SV2A). This protein is located on the membranes of presynaptic vesicles, which are the "storage sacs" for neurotransmitters in the brain. By binding to SV2A, levetiracetam is thought to modulate the release of neurotransmitters. Specifically, it appears to decrease the release of excitatory neurotransmitters like glutamate during periods of high-frequency neuronal activity (seizures) without affecting normal, low-frequency communication between neurons. It also inhibits N-type calcium channels and modulates intraneuronal calcium release, which further stabilizes neuronal excitability.

Levetiracetam provides a broad spectrum of antiepileptic activity. It does not show affinity for conventional receptors like GABA, glycine, or NMDA. Its effect is dose-dependent, and it typically reaches a steady state in the blood within 48 hours of starting a consistent twice-daily regimen. There is no evidence of patients developing a tolerance to its antiepileptic effects over time.

| Parameter | Value |

|---|---|

| Bioavailability | ~100% |

| Protein Binding | <10% |

| Half-life | 7–8 hours (Adults) |

| Tmax | 1 hour (Fasting) |

| Metabolism | Enzymatic hydrolysis (Non-CYP) |

| Excretion | Renal (66% unchanged) |

• Molecular Formula: C8H14N2O2
• Molecular Weight: 170.21 g/mol
• Solubility: Highly soluble in water (>100 g/100 mL)
• Structure: It is the S-enantiomer of etiracetam and is chemically related to the nootropic drug piracetam. It consists of a pyrrolidine ring with an ethyl group and an acetamide group.

Levetiracetam is classified as a Pyrrolidine Anticonvulsant. It is often grouped with newer-generation antiepileptic drugs. A related medication in the same class is Brivaracetam (Briviact), which also binds to SV2A but with much higher affinity.